You are here: Industry Insights > AAV

News List

AskBio, Touchlight Restructure Former JV, Touchlight AAV contractpharma
February 08, 2022
Both parties benefit from co-exclusive rights to independently supply the Adeno-Associated Virus (AAV) market with doggybone DNA.
Gene genies: Oxford Biomedica and Homology Medicines create AAV business pharmatimes
January 28, 2022
Leading gene and cell therapy group, Oxford Biomedica, and Homology Medicines, have announced that the companies will establish...
Astellas Pharma and Dyno Therapeutics Sign Option and License Agreement contractpharma
December 03, 2021
Will collaborate to develop next-gen AAV gene therapy vectors for skeletal and cardiac muscle.
Astellas and Dyno Therapeutics to Collaborate on Research to Develop Next-Gen AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle AmericanPharmaceuticalReview
December 03, 2021
Astellas Pharma Inc. announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus (AAV) vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap™ platform.
Astellas and Dyno Therapeutics to develop AAV gene therapy vectors Pharmaceutical-Technology
December 03, 2021
Astellas Pharma has signed an option and licence agreement with Dyno Therapeutics to develop next-generation adeno-associated virus (AAV) gene therapy vectors for skeletal and cardiac muscle.
Thermo Fisher Launches Gibco AAV Production System ContractPharma
November 12, 2021
Thermo Fisher Scientific has launched the integrated Gibco AAV-MAX Helper Free AAV Production System, a complete, optimized solution that aims to simplify the AAV vector production workflow.
Forge Biologics to provide CDMO support for Solid Biosciences' preclinical gene therapy CPhIonline
October 10, 2021
By providing AAV process development, scale up and cGMP manufacturing services, Forge hopes to bolster Solid's gene therapy pipeline
Collaboration to enable standardisation of AAV quality measurement europeanpharmaceuticalreview
July 29, 2021
US Pharmacopeia to collaborate on assessment of analytical methods for adeno-associated viruses (AAVs) to facilitate the development of reference standards.
Capsida Unveils Next-Generation Gene Therapy Manufacturing contractpharma
July 28, 2021
New 15,000 square foot facility in Thousand Oaks will enable end-to-end gene therapy manufacturing capability.
GentiBio, Forge Biologics Ink Development and Manufacturing Agreement contractpharma
July 19, 2021
GentiBio and Forge Biologics have entered a development and manufacturing partnership to advance GentiBio’s immune tolerance platform.

Previous page 1 2 3 4 Next page